Yahoo Web Search

Search results

1. • Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

     FOX21 Colorado Springs· 6 days ago

     Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically ...

2. • 

     Biogen to buy San Francisco startup developing a drug for kidney disease for $1.2B - Boston Business...

     The Business Journals· 5 days ago

     The Cambridge drugmaker (Nasdaq: BIIB) said on Wednesday it's buying Human Immunology Biosciences,...

3. • Small Business - The Brewton Standard | The Brewton Standard

     The Brewton Standard· 3 days ago

     Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will ...

4. • 

     Johnson & Johnson shares maintain outperform rating at RBC on TREMFYA potential By Investing.com

     Investing.com· 5 days ago

     On Wednesday, RBC (TSX:RY) Capital maintained its positive stance on Johnson & Johnson (NYSE:JNJ),...

5. • Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem...

     Clearfield Progress· 6 days ago

     Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it signed a memorandum of understanding with YASKAWA Electric Corporation (YASKAWA) to begin ...

6. • Small Business - The Andalusia Star-News | The Andalusia Star-News

     The Andalusia Star-News· 2 days ago

     Based on discussions with the European Investment Bank (the "EIB"), one of the components of the Plan could include conversion of a part of the Company...

7. • 

     This Isn’t Your Father’s Marijuana Use | Washington Monthly

     Washington Monthly· 5 days ago

     A new study has documented a remarkable rise in Americans’ use of marijuana. Now, more than 40...

8. • 

     Lyra cuts 75% of staff, looks to sublease Waltham, Watertown facilities - Boston Business Journal

     The Business Journals· 6 days ago

     After a trial of Lyra Therapeutics Inc.'s drug to treat sinus inflammation failed to meet the goals...

9. • 

     Is Madrigal Pharmaceuticals Stock a Buy?

     Motley Fool via Yahoo Finance· 6 days ago

     That likely reflects -- at least in part -- commercialization costs associated with its newly launched therapy. Analysts are excited about Rezdiffra....

10. • Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human...

      Morningstar· 5 days ago

      Biogen Inc. (Nasdaq: BIIB) and Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated ...